Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study

The phase III GALLIUM trial assessed the safety and efficacy of obinutuzumab-based versus rituximab-based immunochemotherapy in patients with previously untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL). At the primary analysis, the trial met its primary end point, demonstrating imp...

Full description

Bibliographic Details
Main Authors: William Townsend, Wolfgang Hiddemann, Christian Buske, Guillaume Cartron, David Cunningham, Martin J.S. Dyer, John G. Gribben, Elizabeth H. Phillips, Martin Dreyling, John F. Seymour, Andrew Grigg, Judith Trotman, Tong-Yu Lin, Xiao-Nan Hong, Dirk Kingbiel, Tina G. Nielsen, Andrea Knapp, Michael Herold, Robert Marcus
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000919

Internet

http://journals.lww.com/10.1097/HS9.0000000000000919

Similar Items